共 50 条
Effect of Paxlovid on Tacrolimus Concentration in Perioperative Kidney Transplant Patients Infected With COVID-19: A Case Report
被引:1
|作者:
Liu, Yuewen
[1
]
Liu, Yanfang
[2
]
Cai, Chaohong
[2
]
Hui, Fuhai
[3
]
Zhang, Yan
[4
]
Wang, Boqian
[1
]
Wang, Xueyi
[1
]
Zhang, Yijian
[1
]
Song, Xing
[1
]
He, Long
[1
]
Yang, Hongwei
[1
]
机构:
[1] Gen Hosp Northern Theater Command, Organ Transplantat Ctr, 5 Guangrong St, Shenyang 110010, Liaoning, Peoples R China
[2] Gen Hosp Northern Theater Command, Dept Clin Trial Ctr, Shenyang, Peoples R China
[3] Shenyang Pharmaceut Univ, Dept Clin Pharm, Shenyang, Peoples R China
[4] Gen Hosp Northern Theater Command, Dept Pharm, Shenyang, Peoples R China
关键词:
D O I:
10.1016/j.transproceed.2023.07.007
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Paxlovid, as a new drug, received emergency approval for the treatment of COVID-19 in China; there is very little experience with kidney transplantation patients taking tacrolimus with perioperative COVID-19 infection. We discontinued tacrolimus on the day of using Paxlovid, and we chose to frequently monitor the concentration of tacrolimus and creatinine early in the course of treatment by enzyme multiplied immunoassay technique (EMIT) and liquid chromatographymass spectrometry (LC-MS/MS). The results show varying degrees of elevation of creatinine levels in 3 patients, and EMIT may overestimate the true concentration of tacrolimus metabolites compared with LC-MS/MS. All the data comply with the Helsinki Congress and the Declaration of Istanbul.
引用
收藏
页码:1822 / 1825
页数:4
相关论文